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Selective Targeting of the KRAS Codon 12 Mutation Sequence by 
Pyrrole–Imidazole Polyamide seco-CBI Conjugates 
Rhys D. Taylor[a], Anandhakumar Chandran[a], Gengo Kashiwazaki[a], Kaori Hashiya[a], Toshikazu 
Bando*[a], Hiroki Nagase[b], Hiroshi Sugiyama*[a, c, d] 
 
Abstract: Mutation of KRAS is a key step in many cancers. 
Mutations occur most frequently at codon 12, but targeting KRAS is 
notoriously difficult. We recently demonstrated selective reduction in 
tumors volume harboring the KRAS codon 12 mutation in a mouse 
model using an alkylating hairpin N-methylpyrrole-N-methylimidazole 
polyamide seco-CBI conjugate (conjugate 4) designed to target the 
KRAS codon 12 mutation sequence. Here, we compared the 
alkylating activity of 4 against three other conjugates also designed 
to target the KRAS codon 12 mutation sequence. Conjugate 4 
displayed greater affinity for the G12D mutation sequence than for 
the G12V sequence. A computer-minimized model suggested that 
conjugate 4 could bind more efficiently to the G12D match sequence 
than to a one-base pair mismatch sequence. Conjugate 4 was 
modified for next-generation sequencing. Bind-n-Seq analysis 
supported the evidence showing that conjugate 4 could target the 
G12D mutation sequence with exceptionally high affinity and the 
G12V mutation sequence with much higher affinity than that for the 
wild-type sequence. 
Introduction 
The RAS family is a known family of oncogenes, such as 
HRAS, NRAS, and KRAS. This family is associated with poor 
prognosis[1,2] and is the most common oncogene family, with 1 in 
3 cancers bearing an RAS mutation.[3,4] Around 90% of 
pancreatic cancers and 50% of colorectal cancers contain a 
KRAS mutation.[5,6] Conventional chemotherapeutic drugs such 
as DNA-alkylating agents, cisplatin, the anthracycline 
doxorubicin, and other antitumor antibiotics such as bleomycin 
and mitomycin-C are used routinely to treat cancer.[7] However, 
these drugs lack selectivity and can attack both healthy cells, 
notably labile cells such as bone marrow and reproductive cells, 
and cancerous cells.  
Although there has recently been some limited success using 
small-molecule inhibitors designed to target KRAS,[8–10] no 
successful clinical inhibitors of KRAS have been developed, 
which has led many to think of KRAS as “undruggable.”[6,11] 
Point mutations most frequently occur at codons 12, 13, and 
61.[12–15] Mutations at codons 12 and 13 cause steric hindrance 
of the KRAS protein through a conformational change that 
inhibits GAP-induced GTP (active) hydrolysis to GDP (inactive) 
and causes the KRAS protein to be permanently activated.[16] 
Therefore, the mutation sequences at codons 12 and 13 are 
therapeutically attractive targets.[17] 
N-methylpyrrole-N-methylimidazole polyamides are an 
important class of small molecules that can bind in a sequence-
specific manner to the DNA minor groove.[18–20] Antiparallel 
pairing of imidazole (Im) opposite pyrrole (Py) recognizes G–C 
base pairs (bps), and a Py–Py pair recognizes A–T or T–A bps. 
γ-Aminobutyric acid (γ) is used as the turn moiety to form a 
hairpin motif that recognizes A–T or T–A bps. For hairpin Py–Im 
polyamides with a chain of five or more continuous Py–Im 
moieties, β-alanine (β) is required to ease the steric hindrance 
and to allow efficient binding to the minor groove, because Py–
Im polyamides are overcurved compared with the DNA minor 
groove.[21-24] The inclusion of β can replace Py, so that β–β, β–Py, 
and Py–β pairings recognize A–T or T–A bps in alkylating Py–Im 
polyamides.[25] It is important to consider the positioning of β 
because it can influence both the binding orientation[26] and the 
binding affinity[27,28] of the Py–Im polyamide in the minor groove. 
The binding of transcription factors can be inhibited to 
selectively silence genes using Py–Im polyamides.[29] However, 
many genes share the same transcription factors, and targeting 
unique sequences in the coding region is preferable. RNA 
polymerase removes Py–Im polyamides during transcription. 
Conjugating an alkylating moiety to a Py–Im polyamide can form 
a covalent adduct with N3 of adenine at a predetermined 
sequence. Alkylating Py–Im polyamides can selectively target 
the coding region that inhibits transcription[30,31] and can 
selectively silence genes.[32] For efficient alkylation, we 
conjugate Py–Im polyamides with the alkylating moiety, 
1,2,9,9a-tetrahydrocyclopropa[1,2-c]benz[1,2-e]indol-4-one 
(CBI)[33–35] via an indole linker.[36] Recently, we demonstrated 
selective targeting of the KRAS codon 13 mutation sequence 
using seco-CBI–Py–Im polyamides.[37] Conjugate 4 has also 
recently been shown to selectively target tumors harboring the 
KRAS codon 12 mutation in a mouse model.[38] Here, we report 
on the selective targeting of the KRAS codon 12 mutation 
sequence using seco-CBI–Py–Im polyamides. Conjugate 4 and 
three other conjugates were designed with the same core 
recognition motif to target the KRAS codon 12 mutation 
sequence, but with the β pairing at various positions (Figure 1). 
The alkylating activity of these compounds was evaluated using 
high-resolution denaturing gel electrophoresis. Based on these 
results, conjugate 4 was selected for further evaluation. Using 
Bind-n-Seq with 10 bp randomized oligonucleotide sequences 
and computer-minimized structures, we confirmed its high 
affinity for the codon 12 mutation sequence over other 
sequences, demonstrating a potential route for gene sequence-
based cancer therapy. 
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Results and Discussion 
Molecular Design and Synthesis of Alkylating Py–Im 
Polyamide Conjugates Targeting the KRAS Codon 12 
Mutation. 
In human and rodent tumors, the most frequent point 
mutations in KRAS are at codon 12 and involve the changes 
GGT→GAT (G12D) and GGT→GTT (G12V),[39] which change 
the amino acid code from glycine to aspartic acid and to valine, 
respectively. Four alkylating hairpin Py–Im polyamides were 
designed with the same core moiety to recognize a 9 bp 
sequence containing the KRAS codon 12 mutation site and to 
alkylate A in the template strand (Figure 1). To strongly block 
RNA polymerase, the DNA alkylation must target the template 
strand.30 Binding occurs in the N–C direction with regard to the 
5ʹ′–3ʹ′ direction of the DNA duplex[40] and recognizes the 
sequences 5ʹ′-TGWTGGCGT-3ʹ′ of the coding strand and 5ʹ′-
ACGCCAWCA-3ʹ′ for the template strand, with W denoting A/T of 
the G12D and G12V sequence. 
The chemical structures of conjugates 1–4 differ only in the 
position of the β pair used in place of two Py moieties, which 
results in different combinations of Py–Py, β–Im, β–Py, and β–β. 
This difference causes minor conformational changes in the 
structures of 1–4, which affect their binding affinity for the DNA 
minor groove.[41,42] The Py–Im polyamide carboxylic acids were 
synthesized by Fmoc solid-phase synthesis on an oxime resin 
for 1, 2, and 4, or on β-Wang resin for 3, followed by cleavage 
using NaOH or TFA, respectively. The Py–Im polyamide 
carboxylic acids were converted into 1–4 by coupling with NH2-
indole-seco-CBI via an activated ester using PyBOP.[43–45] 
Following HPLC purification, conjugates 1–4 were verified by 
reversed-phase HPLC and ESI–TOF mass spectrometry. The 
sequence-specific DNA-alkylating activity of conjugates 1–4 
against the KRAS codon 12 mutation sequence was evaluated 
using high-resolution denaturing gel electrophoresis. 
 
Evaluation of Specific DNA-Alkylating Activities against 
KRAS Codon 12 Sequences. 
The alkylating activity against the KRAS codon 12 mutation 
was evaluated using 5ʹ′-Texas Red-labeled 208 bp DNA 
fragments and an automated DNA sequencer. A 16 bp 
oligonucleotide was ligated into the pGEM-T Easy vector. The 
top T7 strand contained the KRAS G12D sequence 5ʹ′-
ACGCCATCA-3ʹ′, and the bottom SP6 strand contained the 
KRAS G12V sequence 5ʹ′-ACGCCAACA-3ʹ′. 
DNA alkylation was conducted at 25°C for 18 h and was 
then quenched with calf thymus DNA. DNA alkylation was 
visualized by thermal cleavage of the 5ʹ′-Texas Red-labeled DNA 
strands at the alkylated sites,[46] which showed cleavage bands 
quantitatively on the polyacrylamide gel. Sanger sequencing 
was used to identify the alkylation sites.[47–50] Figure 2 shows the 
alkylation by conjugates 1–4 of the T7 DNA strand containing 
the KRAS G12D mutation, and Figure 3 shows the alkylation by 
conjugates 1–4 of the SP6 DNA strand containing the KRAS 
G12V mutation. 
Conjugate 1 displayed very weak alkylation of the G12D 
mutation sequence at 500 nM and 1 µM but failed to show any 
alkylating activity over the entire concentration range for the 
G12V mutation sequence. This can probably be attributed to the  
Figure 1. a) Chemical structures of Py–Im polyamide seco-CBI conjugates 1–
4. b) Schematic representation of DNA alkylation of the KRAS G12D mutation 
sequence. X, Y, Z, M, and N represent the possible substitution of Py for β, 
indicated to the right. W represents A/T. 5ʹ′-GAT-3ʹ′ on the coding strand 
represents the G12D mutation, and 5ʹ′-GTT-3ʹ′ on the coding strand represents 




















































































































































































































































1:#M=β,  N=Py, X=β,  Y=Py, Z=Py 
2:#M=Py, N=β,  X=Py, Y=β,  Z=Py 
3:#M=Py, N=β,  X=Py, Y=Py, Z=β 























Figure 2. Thermally induced strand cleavage of the 208 bp DNA fragments 
containing the G12D mutation sequence were labeled with 5ʹ′-Texas Red (10 
nM). Polyamides 1–4 were incubated for 18 h at 25°C at the following Py–Im 
polyamide concentrations: lane 1=DNA control; lanes 2–6=10, 50, 100, 500, 
and 1000 nM of polyamide 1; lanes 7–11=10, 50, 100, 500, and 1000 nM of 
polyamide 2; lanes 12–16=10, 50, 100, 500, and 1000 nM of polyamide 3; and 
lanes 17–21= 10, 50, 100, 500, and 1000 nM of polyamide 4. 
placement of β at position M (Figure 1). The amino terminus 
contains five continuous heterocyclic Py–Im; this conformation 
would be over curved compared with the minor groove and 
would therefore inhibit the Py–Im polyamide from binding 
effectively and thus inhibit alkylation. This confirms previous 
reports suggesting that β should be included after a maximum of 
four consecutive Py–Im moieties.[21–24] 
 
Conjugate 2 alkylated the G12D mutation site with high 
reactivity (Figure 2). Alkylation was visible from 50 nM and 
potent alkylation at 500 nM and 1 µM. However lower reactivity 
was observed at the G12V site (Figure 3). Mismatch alkylation 
was also observed at three separate sites: mismatch sites 1, 2, 
and 3. Conjugate 2 displayed high reactivity toward mismatch 
site 1 located on the T7 strand, with alkylation comparable to the 
G12D match site. Alkylation was also observed at 500 nM and 1 
µM at mismatch site 2, which is also located on the T7 strand 
(Figure 2). Visible alkylation was also evident at mismatch site 3 
on the SP6 strand at 500 nM and 1 µM (Figure 3). 
Conjugate 3 displayed lower reactivity toward both the G12D 
and G12V target sites and only minor alkylation at 500 nM and 1 
µM. The lower reactivity of conjugate 3 can probably be 
attributed to β at position Z (Figure 1), which is next to the indole 
linker. The consecutive degenerate binding of β and the indole 
linker probably inhibits the efficient binding of the alkylating 
moiety to the minor groove. 
 
 
Figure 3. Thermally induced strand cleavage of 208 bp DNA fragments 
containing the G12V mutation sequence were labeled with 5ʹ′-Texas Red (10 
nM). Polyamides 1–4 were incubated for 18 h at 25°C at the following Py–Im 
polyamide concentrations: lane 1=DNA control; lanes 2–6=10, 50, 100, 500, 
and 1000 nM of polyamide 1; lanes 7–11=10, 50, 100, 500, and 1000 nM of 
polyamide 2; lanes 12–16=10, 50, 100, 500, and 1000 nM of polyamide 3; and 
lanes 17–21= 10, 50, 100, 500, and 1000 nM of polyamide 4. 
Conjugate 4 targeted the G12D with high reactivity, and 
alkylation was observed from 50 nM and potent alkylation at 500 
nM and 1 µM. Lower reactivity was again observed for the G12V  
 
site over the same concentration range. Mismatch alkylation was 
also observed at two separate sites. At mismatch site 1, minor 
alkylation was seen at 50 nM and 100 nM, and higher reactivity 
was seen at 500 nM and 1 µM. Mismatch alkylation at mismatch 
site 3 was also observed at 500 nM and 1 µM but, importantly, 
no mismatch alkylation was observed at mismatch site 2. 
Interestingly, conjugates 2 and 4 had much higher reactivity 
for the G12D mutation sequence, which is the most frequently 
occurring KRAS mutation.[51] Conversely, the reactivity was 
lower for the G12V mutation sequence. The reason for this is not 
clear from the Py–Im polyamide binding rules,[18–20] and further 
investigation is warranted. 
Based on the results of PAGE, substitution of Py with β at 
position M was unsuccessful because the aromatic chain was 
too long; therefore, substitution at position N is preferred. 
Additionally, substitution at position X gives higher reactivity and 
selectivity compared with positions Y and Z. The two 
consecutive Py moieties probably stabilize the indole-seco-CBI 
in the minor groove to allow for efficient alkylation. Therefore, 
the binding specificity of conjugate 4 was investigated further. 
These data support our recently published data demonstrating 
the ability of conjugate 4 to suppress tumor growth selectively in 
mice with tumors harboring the KRAS codon 12 mutation.[38] 
 
 






Molecular Modeling Studies of Conjugate 4. 
To gain further insight into the alkylating reactivity of 
conjugate 4, we performed molecular modeling studies of 
polyamide 4 [5ʹ′-dGCCTACGCCAACAGCTC-3ʹ′/5ʹ′-
dGAGCTGTTGGCGTAGGC-3ʹ′ (G12D match sequence)] and 4 
[5ʹ′-dGCCTACGCCACCAGCTC-3ʹ′/5ʹ′-
dGAGCTGGTGGCGTAGGC-3ʹ′ (1 bp mismatch sequence)] 
(Figure 4). The energy-minimized structure for the G12D 
sequence indicated that conjugate 4 could bind tightly to the 
minor groove of the DNA helix. The model displayed a distance 
of 3.03 Å between the C9 of the cyclopropane subunit of CBI 
and the nucleophilic N3 of adenine. This is within an appropriate 
distance to allow efficient alkylation to occur. The distance 
between the same units for the 1 bp mismatch sequence was 
3.12Å, which is consistent with the evidence of efficient 
sequence-specific alkylation of the G12D sequence. 
Figure 4. a) Energy-minimized structure of the complex between 5 [5ʹ′-
dGCCTACGCCAACAGCTC-3ʹ′/5ʹ′-dGAGCTGTTGGCGTAGGC-3ʹ′] and the 
KRAS G12D sequence. The G12D mutation is highlighted in yellow. The water 
layer, H atoms, and Na+ cations are omitted for clarity. b) Magnified view of the 
alkylation site. The indole-CBI and adenine moieties are highlighted. c) The 
distance between C9 of the cyclopropane subunit of CBI and N3 of adenine, 
and the angle between the C8b and C9 of the cyclopropane and the N3 of 
adenine. d) Table comparing distance and angle of the cyclopropane unit and 
adenine between the match sequence and the 1 bp mismatch sequence. 
 
The angle of the N3-C9-C8b for the G12D sequence was 
150°, thus the cyclopropane ring was positioned in an efficient 
orientation for alkylation to occur.[36] The G12D-minimized 
structure shows that the β–β pairing at positions X and N of 4 
works well to allow the Py–Im polyamide to curve efficiently 
around the DNA helix, while remaining tight inside the minor 
groove. The flexibility of β at position N allows the terminal Py–
Im to hold the indole-seco-CBI close to the nucleophilic N3 of 
the adenine. The distance and angle of the alkylating moiety of 
conjugate 4 are consistent with the evidence showing good 
sequence-specific DNA alkylating reactivity. These results also 
show that careful placement of the β pairing should be 
considered when designing alkylating Py–Im polyamides to 
recognize longer DNA sequences to allow for efficient binding to 
the DNA helix. 
 
High-Throughput Sequencing of Conjugate 5. 
 Bind-n-Seq enables high-throughput sequencing of Py–Im 
polyamide binding sites[52-54] and allowed us to investigate the 
binding sequences of conjugate 4 in much greater detail than 
with PAGE. To investigate the binding specificity of Py–Im 
polyamide 4, conjugate 5 was synthesized. Conjugate 5 
contains the same Py–Im polyamide core as conjugate 4 with 
the addition of PEG12-biotin on the γ turn to facilitate the affinity 
pull down; and the alkylating CBI moiety was substituted with 
dimethylaminopropylamine (Dp) to ensure that alkylation did not 
interfere with the binding. This reduced the recognition 
sequence by 1 to 8 bp (Figure 5b). An 8 bp DNA sequence 
contains 32,896 combinations of possible bp sequences.[55] 
Following incubation of conjugate 5 with 10 bp randomized DNA 
sequences with Ion PGM-compatible adapter sequences, pull 
down with streptavidin beads and affinity purification retained the 
Py–Im polyamide-bound DNA sequences.[56] Following 
amplification by PCR of the retained DNA sequences, high-
throughput sequencing was performed using the Ion PGM 
sequencer and was confirmed using the DREME primary motif 
analysis algorithm.[57] 
According to the bind-n-seq analysis parameter used in 
previous reports, [52-54, 56] the highest enriched sequence is used 
for the binding site motif construction (Figure 5c). Since our top 
three sequences share very close sequence similarity by default 
the Bind-n-seq motif construction program constructed the 
preliminary motif (Figure 5c) from the top three sequences. 
In the Bind-n-Seq analysis shown in Figure 5d, the top-three 
binding sequences represent match sequences for conjugate 5 
with a high fold enrichment. Figure 5b shows the hit-binding 
sequence of conjugate 5, 5ʹ′-ACGCCATC-3ʹ′, which corresponds 
to the G12D mutation sequence that bound with very high 
specificity, with a significant 89-fold enrichment. Third was the 
G12V sequence, which had a considerable 69-fold enrichment. 
Importantly, the second sequence from the Bind-n-Seq analysis 
5ʹ′ACGCCTTC-3ʹ′, with 76-fold enrichment, is also a match 
sequence for conjugate 5 according to the established binding 
rules.[18–20] The fold enrichment declined drastically for the 
mismatch binding sites, suggesting unfavorable binding; for 
example, by the ninth place, the fold enrichment was less than 
half that of the G12D sequence. Importantly, the corresponding 
WT KRAS sequence 5ʹ′-ACGCCACC-3ʹ′ was located at position 
354, with a nonsignificant fourfold enrichment. These results 
clearly show that the Py–Im polyamide motifs of 4 and 5 
targeted the KRAS codon 12 mutation sequences, especially the 
G12D mutation sequence, with high affinity.  
 
 







Figure 5. a) Structure of Py–Im polyamide 5. 5 contained the same core 
moiety as 4, but the CBI unit was replaced with Dp and PEG20-biotin was 
conjugated to the γ turn. b) Schematic representation of the target KRAS-
binding sequence. c) Primary binding motif identified using Bind-n-Seq and 
next-generation sequencing. This sequence corresponded to the G12D 
mutation sequence. d) Table of the top 10 binding sequences for 5 identified 
by Bind-n-Seq. Note the G12V sequence ranked third and the KRAS WT 
sequence ranked at 354. 
 
The mismatch site 1 observed on the gel (Figure 2), 
AGGCAATCA was also partially observed in the Bind-n-Seq 
experiments as a 7 base site AGGCAAT with 4.2 fold 
enrichment. Also mismatch site 3, ATGCATCCA was partially 
observed for the reverse 7 base sites, TACGAAG and 
TACGATG with 2.6 and 2.4 fold enrichment respectively. These 
low enrichments of the mismatch sites could be attributed to a 
broad context of sequences used in Bind-n-Seq. In other words, 
alkylation of the mismatch sites observed in PAGE was 
overestimated due to a restricted availability of sequences, and 
the results from Bind-n-Seq reflected more actual binding 
characteristics of Py-Im polyamide. 
Even without the seco-CBI moiety, the G12D sequence was 
the preferred target for the Py–Im polyamide followed by the 
G12V mutation sequence, which is in agreement with the PAGE 
results. Intriguingly, mismatch sites 1 (5ʹ′-AGGCAATC-3ʹ′) or 2 
(5ʹ′-TATTCTAT-3ʹ′) could not be detected in the Bind-n-Seq 
analysis, suggesting that the CBI moiety might play a role in the 




Mutant KRAS is a therapeutically important target, and there are 
at present no drugs that successfully target mutant KRAS. 
Conventional drugs aim at inhibiting the KRAS protein or 
downstream targets. We decided to take a different approach by 
targeting the KRAS codon 12 mutation directly. We evaluated 
the sequence-specific alkylating activity of four Py–Im polyamide 
conjugates in targeting the KRAS codon 12 G12D and G12V 
mutation sequences. Two of the alkylating Py–Im polyamides 
displayed high reactivity for the target site; conjugate 4 displayed 
the highest selectivity and was selected for further evaluation. 
The computer-minimized structure of the G12D mutation 
sequence suggested that the structural motif of 4 was 
appropriate for efficient sequence-specific alkylation of the target 
sequence. High-throughput sequencing (Bind-n-Seq) revealed 
the binding specificity of conjugate 5 against 10 bp randomized 
sequences. Conjugate 5 displayed significant affinity for the 
KRAS codon 12 mutation sequences with 89- and 69-fold 
enrichment for the G12D and G12V sequences, respectively, but 
only fourfold enrichment for the WT sequence. The 9 base pair 
recognition of Py-Im polyamide 4 allows the recognition of 
approximately 9,121 sites in the human genome (GRCh38/hg38) 
containing the KRAS match sequence for preferential 
alkylation.[38] Our results strongly suggest that seco-CBI Py–Im 
polyamides are potential agents for the treatment of cancer 
based on individual genetic mutations. This approach may help 
minimize side effects and overcome the problem of drug 
resistance. Specifically targeting the KRAS codon 12 mutation 
sequence may be a viable therapeutic route for targeting tumors 
harboring mutant KRAS. 
Experimental Section 
General Methods. Reagents and solvents were purchased from 
standard suppliers and used without further purification. High-
performance liquid chromatography (HPLC) analysis was performed with 
a JASCO PU-2080 Plus HPLC pump and using a JASCO 807-IT HPLC 
UV/Vis detector and a Chemcobond 5-ODS-H reversed-phase column 
(4.6 x150 mm) in 0.1% TFA in water with acetonitrile as eluent at a flow 
rate of 1.0 mL min-1 with detection at 254 nm. Electrospray ionization 
time-of-flight mass spectrometry (ESI-TOF- MS) was produced on a Bio-
TOF II (Bruker Daltonics) mass spectrometer using a positive ionization 


































































































PSSM-8 (Shimadzu) with computer-assisted operation system at a 20 
µmol scale by using Fmoc chemistry. The oligonucleotides, 5’-Texas Red 
labelled primers, and cold primers were purchased from Sigma–Aldrich. 
Ex Taq DNA polymerase was purchased from Takara. Thermo Sequence 
core sequencing kit and loading dye (formamide with fuchsin red) were 
purchased from GE Healthcare. Polymerase Chain Reaction (PCR) was 
performed on an iCycler (BIO-RAD). Long Ranger gel solution (50%) was 
purchased from FMC bioproducts. Polyacrylamide gel electrophoresis 
was performed on a HITACHI 5500-S DNA sequencer, and data were 
analysed by FLAGLYS version 2 software (HITACHI). NH2 –indole-seco-
CBI was prepared by previous methods.[33–36] Oxime resin (200– 400 
mesh) was purchased from Peptides International and Novabiochem. 
Randomized oligonucleotides were modified using the Ion torrent PGM 
sequencer (Life Technologies). 
Solid-Phase Synthesis of Py-Im Polyamides. Py-Im polyamides 
supported by oxime resin (for the synthesis of the conjugates 1, 2, 4 and 
5) or β-Wang resin (for conjugate 3) were prepared in a stepwise reaction 
by reported fluorenylmethyloxycarbonyl (Fmoc) solid-phase synthesis 
using Fmoc-Py-CO2H, Fmoc-Im-CO2H, Fmoc-PyIm-CO2H, Fmoc-β-CO2H, 
Fmoc-GABA-OH (for conjugates 1-4), Boc-Dab (Fmoc) –OH (for 
conjugate 5), O- (1H-6-chlorobenzotriazole-1-yl)-1,1,3,3-
tetramethyluronium hexafluorophosphate (HCTU), N, N-
diisopropylethylamine (DIEA), 1-methyl-2-pyrrolidone (NMP).[18] 
Cleavage from the oxime resin was carried out in basic conditions using 
2M NaOH and 1, 4-dioxane (1:1) at 55°C for 3 h, and β-Wang resin using 
TFA, water and triisopropylsilane (95:2.5:2.5) at room temperature for 30 
min. For 1, 2, 4 and 5, the resulting carboxylic acids were acidified with 
CH3COOH to pH 6, precipitated with Et2O, washed with milliQ water and 
lyophilized. The target carboxylic acid 3 was collected after precipitation 
with Et2O. The corresponding crudes were used without further 
purification in the coupling reaction with NH2-indole-seco-CBI. 
Synthesis of Conjugate 1 by the Coupling with NH2-Indole seco-CBI. 
A solution of Py-Im polyamide carboxylic acid 1 (1.0 mg, 0.66 µmol), 
DMF (100 µL), DIEA (0.5 µL, 2.86 µmol), and benzotriazol-1-yl-
oxytripyrrolidinophosphonium hexafluorophosphate (PyBOP, 1.0 mg, 
1.95 µmol) were stirred for 30 min at RT. The formation of the activated 
1-hydroxybenzotriazole ester was checked by analytical HPLC (tR = 13.8 
min, 0.1% TFA/MeCN, linear gradient 0–100%, 0–20 min); then, NH2 -
indole-seco-CBI (0.6 mg, 1.58 µmol) was added and the mixture was 
stirred overnight at room temperature under a N2 atmosphere. Et2O was 
added and the supernatant was removed. The crude was washed with 
Et2O and CH2Cl2, followed by HPLC purification (0.1% TFA/ MeCN, 
linear gradient 20–65%, 0–30 min). After collecting the main peak 
fraction and lyophilization, conjugate 1 was obtained as a yellow solid 
(1.0 mg, 0.54 µmol, 80% yield). MS (ESI-TOF): m/z calcd for 
C89H94ClN31O162+ [M+2H]2+ 943.8586; found 943.8555. 
Following the same synthetic procedure conjugates 2-4 were 
synthesized: 
Conjugate 2 was obtained as a yellow powder. MS (ESI-TOF): m/z calcd 
for C89H94ClN31O162+ [M+2H]2+ 943.8586; found 943.8482; HPLC: tR = 
13.8 min (0.1% TFA/MeCN, linear gradient 0–100%, 0–20 min).  
Conjugate 3 was obtained as a yellow powder. MS (ESI-TOF): m/z calcd 
for C89H94ClN31O162+ [M+2H]2+ 943.8586; found 943.8552; HPLC: tR = 
13.7 min (0.1% TFA/MeCN, linear gradient 0–100%, 0–20 min).  
Conjugate 4 was obtained as a yellow powder. MS (ESI-TOF): m/z calcd 
for C89H94ClN31O162+, [M+2H]2+ 943.8586; found 943.8572; HPLC: tR = 
13.9 min (0.1% TFA/MeCN, linear gradient 0–100%, 0–20 min) 
Synthesis of Conjugate 5 
NO2-indole-3-dimethylaminopropylamine (DMAPA) (6 mg, 20 µmol) was 
reduced under a H2 atmosphere with Pd/C (5 mg, 46 µmol) in DMF (400 
µL) for 2 h. The Pd/C was removed by filtration and the remaining 
solution was immediately used in the next step. Simultaneously, DIEA 
(0.5 µL, 2.86 µmol) and PyBOP (1.0 mg, 1.95 µmol) were added to a 
solution of Py-Im polyamide carboxylic acid 5 (1.0 mg, 0.38 µmol) in DMF 
(50 µL). The reaction mixture was stirred for 30 min at room temperature. 
After the conversion from the carboxylic acid into the activated 1-
hydroxybenzotriazole ester, the NH2-indole-DMAPA solution was added 
and stirred overnight at room temperature under N2 atmosphere. Et2O 
was added and the supernatant was removed. The crude was washed 
with Et2O and CH2Cl2 and dried. Boc deprotection was carried out in TFA 
(300 µL) and DCM (300 µL) for 1 h at room temperature. The solvent 
was removed, and the remaining solid was filtered, washed with milliQ 
(500 µL) and subjected to HPLC purification (0.1% TFA/MeCN 30–75% 
linear gradient, 0–30 min). The peak fraction containing the product was 
collected, and lyophilized. The purified compound was dissolved in DMF 
(100 µL) and DIEA (0.5 µL, 2.86 µmol) and NHS-PEG12-Biotin was added 
and stirred for 1 h at room temperature. Et2O was added and the 
supernatant was removed. Conjugate 5 was washed with CH2Cl2 and 
ET2O to give a light brown powder (0.5 mg, 0.19 µmol, 50%). MS (ESI-
TOF): m/z calcd for C118H164N36O30S2+ [M+2H]2+ 1298.6062; found: 
1298.5363; HPLC: tR = 10.9 min (0.1% TFA/ MeCN, linear gradient 0–
100%, 0–20 min). 
Cloning of Plasmid DNA 
Oligonucleotides were purchased from Sigma–Aldrich and annealed at a 
concentration of 10 µM, followed by ligation into the pGEM-T Easy vector 
(Promega). Escherichia coli DH5α competent cells (TOYOBO) were 
transformed and cultured overnight at 37 °C on an LB plate with 32 µg of 
X-gal (20 mg mL-1), 25 µL/IPTG 100 mM, and 100 µg mL-1 ampicillin. 
White colonies were identified by colony PCR in 20 µL of the reaction 
mixtures containing 250 nM of each primer (SP6 primer, 5’-
TATTTAGGTGACACTATAG-3’; T7 primer, 5’-
TAATACGACTCACTATAGGG-3’), 200 µM dNTPs (Sigma Aldrich), two 
units of Taq polymerase, and 1xThermoPol reaction buffer (New England 
Bio Labs). Amplification of the DNA fragments was carried out incubating 
at 95 °C for 5 min, followed by 35 cycles of 95 °C for 35 s, 50 °C for 35 s, 
72 °C for 30 s, with a final extension step of 72 °C for 7 min. The 
appropriate colony was selected and transferred to 5 mL of LB medium 
with 100 mg mL-1 ampicillin and cultured overnight at 37 °C. The 
plasmids were extracted using a GenElute Plasmid Miniprep Kit (Sigma 
Aldrich) and identified by PCR (program and reaction mixtures were the 
same as above). The 5’-Texas Red-modified 208 bp DNA fragment was 
prepared by PCR with 5’-Texas Red-modified SP6 and T7 primers from 1 
ng L-1 of the 31 bp fragments 5’-
GCCTACGCCAACAGCGCTGATGGCGTAGGCA-3’/5’-
GCCTACGCCATCAGCGCTGTTGGCGTAGGCA-3’ inserted into the 
pGEM-T Easy vector (program and reaction mixtures were the same as 
above). Fragments were purified by GenElute PCR Clean-up Kit (Sigma 
Aldrich), and their concentrations were determined by UV absorption. 
High-Resolution Gel Electrophoresis 
The 5’-Texas Red labelled 208 bp DNA fragment was prepared by PCR 
using the plasmid with inserts described above and the 5’-Texas Red 











AATTCGCCCTATAGTGAGTCGTATTA-3’. Obtained 5’-Texas Red 
labelled DNA fragments were purified using PCR-Clean Up Kit (Sigma) 
and their concentrations were determined by UV absorption. A reaction 
mixture (10 µL) containing each of alkylating conjugates, a 5’-Texas Red 
labelled DNA fragment (10 nM, duplex concentration), and 50 mM 
sodium phosphate buffer (pH 7.0) was incubated for 18 h at 25 °C. The 
samples were quenched by the addition of 1 mM calf thymus DNA (1 µL) 
and then heated at 95°C for 5 min to cleave the DNA strands at the 
specific alkylation sites. After the removal of solvents under reduced 
pressure, loading dye (7 µL) was added. The samples were heated at 
95 °C for 25 min and immediately cooled on ice. Samples (1.2 µL) were 
subjected to electrophoresis on 6% denaturing polyacrylamide gel using 
Hitachi 5500-S DNA Sequencer.  
Molecular Modelling Studies on the DNA Complex of Conjugate 4 
Minimizations were performed with the Discover (MSI, San Diego, CA) 
program using CVFF force-field parameters. The starting structure was 
constructed using Insight II program and the builder module of the 
program using standard bond lengths and angles. Where the three upper 
and lower sides of Watson–Crick base pairs were fixed, conjugate 4 was 
inserted into the 5’- dGCCTACGCCAACAGCTC-3’/5’-
dGAGCTGTTGGCGTAGGC-3’ duplex (match sequence) and 5’- 
dGCCTACGCCACCAGCTC-3’/5’-dGAGCTGGTGGCGTAGGC-3’ duplex 
(1 bp mismatch sequence). Thirty-four Na+ cations were placed at the 
bifurcating position of the O-P-O angle at a distance of 2.21 Å from the 
phosphorus atom. The resulting complex was soaked in a 15 Å layer of 
water. The layer of water was minimized without constraints to the stage 
where the rms was less than 0.001 kcal mol-1Å using the steepest and 
then the conjugate algorithm; successively the whole complex was also 
minimized in the same way. 
Bind-n-Seq: 
Bind-n-Seq52-54 and subsequent analysis to evaluate the binding affinity 
of conjugate 5 towards 10 bp randomized sequences were modified the 
Ion torrent PGM sequencer (Life Technologies). Randomized 
oligonucleotides with high-throughput sequencing platform-specific 
adapters were synthesized according to the literature procedures.[56] All 
barcoded Bind-n-Seq 92 mers were synthesized by Sigma Aldrich 
machine mixing, standard desalting purification, 5'-
CCATCTCATCCCTGCGTGTCTCCGACTCAGXXXXXXXXXXNNNNNN
NNNNAATCACCGACTGCCCATAGAGAGGAAAGCGGAGGCGTAGTG
G-3`. The barcode represented by XXXXXXXXXX, are 10-letter barcodes 
used as per Ion torrent sequencing technologies, and N represents the 
randomized sequence. Adapter ligated oligonucleotides (3 µM) were 
duplexed by primer extension with the adapter-specific primer 5`-
CCACTACGCCTCCGCTTTCCTCTCTA-3` (9 µM) in 25 µL reactions 
containing GoTaq Green (Promega) PCR master mix (2x) with Mg2+ (2 
mM). The primer extension reactions were performed at 95 °C (3 min), 
60 °C (2 min), 70 °C (5 min), and then 4 °C in a thermocycler (Bio- Rad). 
The binding reaction was performed using duplex DNA and conjugate 5-
bound DNA that was enriched followed by Next Generation Sequencing. 
To count the number of conjugate 5 enriched unique DNA sequences, 
MERMADE with the k-mer sliding window (k = 8 bp) and a new pipeline 
for Bind- n-Seq analysis (http://korflab.ucdavis.edu/Datasets/BindNSeq) 
were used. Highly enriched motifs were confirmed with DREME primary 
motif analysis.[57] 
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(Py-Im) polyamide seco-CBI 
Conjugates target the Kras codon 12 
mutation with high affinity and 
specificity. Following optimization of 
the β-alanine pairings of four Py-Im 
polyamide conjugates for sequence 
specific alkylation, conjugate 5 was 
synthesized for comprehensive 
evaluation of Py-Im polyamides 
sequence specificity for the Kras 
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Selective	  Targeting	  of	  the	  KRAS	  Codon	  12	  Mutation	  Sequence	  by	  
Pyrrole-­‐Imidazole	  Polyamide	  seco-­‐CBI	  Conjugates	  	  Rhys	  D.	  Taylor[a],	  Anandhakumar	  Chandran[a],	  Gengo	  Kashiwazaki[a],	  Kaori	  Hashiya[a],	  Toshikazu	  Bando*[a],	  Hiroki	  Nagase[b],	  Hiroshi	  Sugiyama*[a,	  c,	  d]	  	   	  
List	  of	  top	  50	  Bind-­‐n-­‐Seq	  sequences	  for	  Py-­‐Im	  polyamide	  5	  with	  their	  fold	  enrichment	  	  	  	  
Rank	   Sequence	   Fold-­‐	  
enrichment	  
1	   ACGCCATC	   89.097	  2	   ACGCCTTC	   76.887	  3	   ACGCCAAC	   69.049	  4	   ATGAAGGC	   64.357	  5	   ATGATGGC	   59.01	  6	   AACGCCAT	   53.967	  7	   CGCCATCA	   53.508	  8	   GCCTTCAA	   44.989	  9	   CGCCAACA	   44.346	  10	   AACGCCAA	   43.933	  11	   ATGGCGTG	   43.67	  12	   CGCCTTCA	   43.474	  13	   AACGCCTT	   42.673	  14	   GCCATCAA	   41.35	  15	   GATGGCGA	   37.998	  16	   AGATGGCG	   36.909	  17	   GCCTTCAC	   36.587	  18	   ACGATGGC	   36.426	  19	   GCCATCAC	   34.206	  
20	   ACGAAGGC	   34.005	  21	   ATGGCGTA	   33.954	  22	   ATGGCGTC	   33.872	  23	   AAGATGGC	   33.394	  24	   CTGAAGGC	   31.669	  25	   ATGTTGGC	   31.45	  26	   CAGATGGC	   31.216	  27	   GCCATCTA	   31.148	  28	   CTGATGGC	   30.388	  29	   CACGCCAA	   28.893	  30	   GCCAACAA	   28.527	  31	   GCCAACAC	   28.487	  32	   AAGGCGTA	   28.268	  33	   TACGCCAA	   28.267	  34	   CGATGGCG	   27.318	  35	   AATGGCGT	   27.023	  36	   AAGGCGTG	   26.651	  37	   GCCATCGA	   25.266	  38	   GACGCCAA	   24.57	  39	   ACGCCATA	   23.506	  40	   GAAGGCGA	   23.445	  41	   GAACGCCA	   22.484	  42	   GCCTTCGA	   21.442	  
43	   AGTTGGCG	   21.399	  44	   GAGATGGC	   21.194	  45	   ATCGCCAT	   20.564	  46	   CTGTTGGC	   20.173	  47	   CCGATGGC	   19.686	  48	   CAGAAGGC	   19.578	  49	   TAACGCCA	   18.75	  50	   GCCTTCTA	   18.617	  	  
